ClinicalTrials.gg
RecruitingNCT07401771Updated Aug 20, 2026

Exercise Cardiovascular Magnetic Resonance In Heart Failure With Preserved Ejection Fraction

An observational study in Heart Failure With Preserved Ejection Fraction, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Heart Failure by Mayo Clinic — 16 open to participants now, 17 under way, none of them phase 3. Heart Failure · Mayo Clinic.

Planned enrollment
4th of 18
400 · median 63
Started
2026
with 4 others
Observational
21 of 69
6 open now
Primary completion
2028-03
later than 11 of 16 live
Registered
67th of 69
by date

Among the 69 studies in Heart Failure by Mayo Clinic, this one is the 4th largest by planned enrollment of the 18 observational ones that give a count, is one of 5 that started in 2026, is one of 21 observational ones, reaches primary completion later than 11 of the 16 other live ones, and was the 67th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 69 studies in Heart Failure by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Heart Failure by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to internally validate low-field Ex-CMR as a noninvasive tool for diagnosing, phenotyping, and risk stratifying HFpEF in patients with exertional dyspnea.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be identified from Mayo Clinic Cardiac Cath lab appointment lists.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. obtained
  2. Three groups will be enrolled:

    1. HFpEF (cardiologist-adjudicated diagnosis as verified by PI, EF≥50%)
    2. Non-cardiac dyspnea (patients have dyspnea but were found on invasive exercise testing not to have HFpEF).
    3. Healthy volunteers with no history of dyspnea or effort intolerance.

Exclusion criteria

Exclusion Criteria:

  1. for low-field CMR, as indicated in MRI safety screening checklist (Research Document #1)
  2. Patient inability or unwillingness to undergo Ex-CMR
  3. Cardiac implants, mechanical or biological valve, causing artifacts that compromise the quality of data
  4. Hospitalization for heart failure in the preceding 30 days.
  5. Large R-R interval variation, caused by frequent premature ventricular contractions or non-sinus rhythms such as persistent atrial fibrillation, which, in the opinion of the investigators, compromises the quality of data acquisition, image analysis and disrupts the consistency of the cohorts
  6. Myocardial infarction or unstable angina pectoris
  7. Planned coronary, carotid, or peripheral artery revascularization
  8. Other causes of dyspnea as indicated in patients' medical history based upon the opinion of the PI, such as restrictive cardiomyopathy or infiltrative conditions (e.g., amyloidosis), hypertrophic obstructive cardiomyopathy, primary pulmonary arterial hypertension, more than moderate , right heart failure due to pulmonary disease, complex congenital heart disease, severe anemia, or more than moderate mitral or aortic heart valve disease).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • HFpEF (Heart Failure with Preserved Ejection Fraction)

    Diagnostic Test: Exercise Cardiovascular Magnetic Resonance

  • Non-cardiac dyspnea

    Diagnostic Test: Exercise Cardiovascular Magnetic Resonance

  • Healthy Volunteers

    Diagnostic Test: Exercise Cardiovascular Magnetic Resonance

Interventions

  • Diagnostic testExercise Cardiovascular Magnetic Resonance

    Exercise Cardiovascular Magnetic Resonance is a non-invasive imaging technique that combines cardiovascular magnetic resonance (CMR) with exercise stress testing.

06

What researchers measure

Primary outcomes

  1. Number of heart failure hospitalizations

    Number of heart failure hospitalizations will be determined by the number of patients admitted to the hospital due to heart failure complications.

    Time frame: Baseline

  2. Number of cardiac deaths

    The number of cardiac deaths will include all patients whose death is attributable to a cardiac cause.

    Time frame: Baseline

Secondary outcomes

  1. Number of deaths

    The number of deaths will include all patient deaths, regardless of cause.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2028, 16 months later.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 16 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartEst.
Nov 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07401771
Lead sponsor
Mayo Clinic
Responsible party
Barry Borlaug (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Feb 10, 2026
Start date
Nov 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Annabelle Fuenffinger
Contact
Fuenffinger.Annabelle@mayo.edu
507-422-3801
Barry Borlaug, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion